Most-Upgraded StocksMost-UpgradedNASDAQ:ALNY Alnylam Pharmaceuticals (ALNY) Stock Price, News & Analysis $234.84 -3.04 (-1.28%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$233.42▼$240.3150-Day Range$146.93▼$261.0252-Week Range$141.98▼$263.73Volume524,474 shsAverage Volume882,296 shsMarket Capitalization$29.70 billionP/E RatioN/ADividend YieldN/APrice Target$256.73 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Alnylam Pharmaceuticals alerts: Email Address Alnylam Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside9.3% Upside$256.73 Price TargetShort InterestBearish3.55% of Shares Sold ShortDividend StrengthN/ASustainability-1.52Upright™ Environmental ScoreNews Sentiment0.61Based on 19 Articles This WeekInsider TradingSelling Shares$15.29 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.99) to ($2.38) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.37 out of 5 starsMedical Sector331st out of 936 stocksPharmaceutical Preparations Industry154th out of 436 stocks 2.3 Analyst's Opinion Consensus RatingAlnylam Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 16 buy ratings, 8 hold ratings, and no sell ratings.Amount of Analyst CoverageAlnylam Pharmaceuticals has been the subject of 18 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Alnylam Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.55% of the outstanding shares of Alnylam Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAlnylam Pharmaceuticals has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Alnylam Pharmaceuticals has recently increased by 22.01%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlnylam Pharmaceuticals does not currently pay a dividend.Dividend GrowthAlnylam Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAlnylam Pharmaceuticals has received a 63.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Gene therapy medication", "Clinical research services", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Alnylam Pharmaceuticals is -1.52. Previous Next 2.0 News and Social Media Coverage News SentimentAlnylam Pharmaceuticals has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Alnylam Pharmaceuticals this week, compared to 9 articles on an average week.Search InterestOnly 10 people have searched for ALNY on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Alnylam Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alnylam Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,287,984.00 in company stock.Percentage Held by InsidersOnly 1.50% of the stock of Alnylam Pharmaceuticals is held by insiders.Percentage Held by Institutions92.97% of the stock of Alnylam Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alnylam Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Alnylam Pharmaceuticals are expected to grow in the coming year, from ($3.99) to ($2.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alnylam Pharmaceuticals is -87.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alnylam Pharmaceuticals is -87.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Alnylam Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad MarketBeatWe just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.Start Your Risk-Free Trial Here About Alnylam Pharmaceuticals Stock (NASDAQ:ALNY)Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.Read More ALNY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALNY Stock News HeadlinesJuly 13, 2024 | insidertrades.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Yvonne Greenstreet Sells 7,093 SharesJune 27, 2024 | insidertrades.comInsider Selling: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Sells 1,198 Shares of StockJuly 26, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.June 27, 2024 | insidertrades.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CFO Jeffrey V. Poulton Sells 1,605 SharesJuly 25 at 5:12 AM | americanbankingnews.comAlnylam Pharmaceuticals (ALNY) Set to Announce Quarterly Earnings on ThursdayJuly 24 at 10:56 PM | markets.businessinsider.comIonis Pharmaceuticals’ ION582: Promising Angelman Syndrome Drug Faces Clinical and Commercial UncertaintiesJuly 24 at 7:17 AM | ca.finance.yahoo.comALNY Aug 2024 180.000 callJuly 23 at 6:40 AM | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $220.00 at Cantor FitzgeraldJuly 26, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.July 23 at 3:26 AM | americanbankingnews.comWilliam Blair Weighs in on Alnylam Pharmaceuticals, Inc.'s Q1 2025 Earnings (NASDAQ:ALNY)July 22, 2024 | finance.yahoo.comMarket Sentiment Around Loss-Making Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)July 20, 2024 | msn.comHow the CrowdStrike glitch derailed the days of normal BostoniansJuly 19, 2024 | finance.yahoo.comAlnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial ResultsJuly 19, 2024 | msn.comAlnylam Stock Is a Blockbuster Biopharma In the MakingJuly 18, 2024 | investorplace.comAlnylam Stock Is a Blockbuster Biopharma In the MakingJuly 17, 2024 | americanbankingnews.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $253.55 Average PT from BrokeragesJuly 15, 2024 | stocknews.com3 Biopharma Stocks to Buy for Long-Term GrowthJuly 11, 2024 | investorplace.com35% Surge Just the Beginning? Alnylam’s Stock Poised for Massive Gains on Heart Drug Success.See More Headlines Receive ALNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/26/2024Next Earnings (Confirmed)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ALNY CUSIP02043Q10 CIK1178670 Webwww.alnylam.com Phone(617) 551-8200Fax617-551-8101Employees2,100Year Founded2002Price Target and Rating Average Stock Price Target$256.73 High Stock Price Target$400.00 Low Stock Price Target$159.00 Potential Upside/Downside+8.6%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage24 Analysts Profitability EPS (Most Recent Fiscal Year)($2.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-440,240,000.00 Net Margins-16.58% Pretax Margin-16.21% Return on EquityN/A Return on Assets-8.92% Debt Debt-to-Equity RatioN/A Current Ratio3.17 Quick Ratio3.07 Sales & Book Value Annual Sales$1.83 billion Price / Sales16.35 Cash FlowN/A Price / Cash FlowN/A Book Value($1.76) per share Price / Book-134.29Miscellaneous Outstanding Shares126,490,000Free Float124,595,000Market Cap$29.90 billion OptionableOptionable Beta0.37 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Yvonne L. Greenstreet M.B.A. (Age 61)MBChB, CEO & Director Comp: $2.15MMr. Jeffrey V. Poulton M.B.A. (Age 56)CFO & Executive VP Comp: $1.05MDr. Akshay K. Vaishnaw M.D. (Age 61)Ph.D., Chief Innovation Officer & Member of the Scientific Advisory Board Comp: $1.12MDr. Pushkal P. Garg M.D. (Age 56)Chief Medical Officer and Executive VP of Development & Medical Affairs Comp: $1.06MMr. Tolga Tanguler M.B.A. (Age 51)Executive VP & Chief Commercial Officer Comp: $971.3kMr. Timothy J. MainesChief Technical Operations & Quality OfficerDr. Kevin Joseph Fitzgerald Ph.D. (Age 55)Senior VP, Head of Research & Chief Scientific Officer Ms. Christine Regan Lindenboom (Age 43)Senior VP of Investor Relations & Corporate Communications Mr. Piyush Sharma J.D.Chief Ethics & Compliance OfficerMr. Evan Lippman M.B.A.Chief Corporate Development & Strategy OfficerMore ExecutivesKey CompetitorsHorizon Therapeutics PublicNASDAQ:HZNPRoyalty PharmaNASDAQ:RPRXBeiGeneNASDAQ:BGNESarepta TherapeuticsNASDAQ:SRPTMyoKardiaNASDAQ:MYOKView All CompetitorsInsiders & InstitutionsEFG Asset Management North America Corp.Sold 1,362 shares on 7/26/2024Ownership: 0.015%Liontrust Investment Partners LLPBought 4,933 shares on 7/26/2024Ownership: 0.004%Allspring Global Investments Holdings LLCBought 91 shares on 7/26/2024Ownership: 0.000%Baillie Gifford & Co.Sold 590,921 shares on 7/25/2024Ownership: 4.769%Everhart Financial Group Inc.Bought 1,322 shares on 7/24/2024Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions Should I Buy Alnylam Pharmaceuticals Stock? ALNY Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Alnylam Pharmaceuticals, Inc.: Alnylam Pharmaceuticals has received positive ratings from multiple equity research analysts, with an average target price of $245.14, indicating potential for growth. Recent insider trading activity, such as Director Amy W. Schulman selling shares at $148.60, can provide insights into the company's performance and future prospects. Strong institutional investor interest, with major firms like Vanguard Group Inc. and Wellington Management Group LLP increasing their stakes, signaling confidence in the company's long-term potential. Analyst price targets have been revised upwards, with firms like TD Cowen and Citigroup raising their price objectives, suggesting a positive outlook for the stock. Alnylam Pharmaceuticals' current stock price of $153.86 presents a potential buying opportunity for investors looking to enter at a relatively lower price point. Cons Investors should be bearish about investing in Alnylam Pharmaceuticals, Inc. for these reasons: Despite positive analyst ratings, there is always inherent risk in the biopharmaceutical industry due to factors like regulatory challenges, clinical trial outcomes, and competition. Volatility in the stock price of Alnylam Pharmaceuticals, as seen with fluctuations in trading volume and price movements, may pose risks for short-term investors. Market uncertainties, especially in the healthcare sector, can impact the company's performance and stock valuation, leading to unpredictable returns for investors. Dependency on successful drug development pipelines and regulatory approvals for revenue generation, which can be a lengthy and uncertain process in the pharmaceutical industry. Potential macroeconomic factors, such as changes in healthcare policies or global economic conditions, could influence the company's financial performance and stock price. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, June 28, 2024. Please send any questions or comments about these Alnylam Pharmaceuticals pros and cons to contact@marketbeat.com. ALNY Stock Analysis - Frequently Asked Questions How have ALNY shares performed this year? Alnylam Pharmaceuticals' stock was trading at $191.41 at the beginning of the year. Since then, ALNY stock has increased by 22.7% and is now trading at $234.84. View the best growth stocks for 2024 here. How were Alnylam Pharmaceuticals' earnings last quarter? Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) announced its quarterly earnings results on Thursday, May, 2nd. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.23. Alnylam Pharmaceuticals's revenue was up 54.8% on a year-over-year basis. What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO? 65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are Alnylam Pharmaceuticals' major shareholders? Alnylam Pharmaceuticals' top institutional shareholders include Baillie Gifford & Co. (4.77%), Sumitomo Mitsui Trust Holdings Inc. (0.22%), Assenagon Asset Management S.A. (0.10%) and Portman Square Capital LLP. Insiders that own company stock include Yvonne Greenstreet, Jeffrey V Poulton, Akshay Vaishnaw, Michael W Bonney, Pushkal Garg, Kevin Joseph Fitzgerald, Laurie Keating, Amy W Schulman, Tolga Tanguler, Steven M Paul, David E I Pyott, Indrani Lall Franchini and John Maraganore. View institutional ownership trends. How do I buy shares of Alnylam Pharmaceuticals? Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Alnylam Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI) and Mylan (MYL). This page (NASDAQ:ALNY) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.